Abeona Therapeutics Inc (NASDAQ:ABEO) — Market Cap & Net Worth
Market Cap & Net Worth: Abeona Therapeutics Inc (ABEO)
Abeona Therapeutics Inc (NASDAQ:ABEO) has a market capitalization of $292.09 Million ($292.09 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15070 globally and #3392 in its home market, demonstrating a -1.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Abeona Therapeutics Inc's stock price $5.43 by its total outstanding shares 57049023 (57.05 Million). Analyse ABEO cash flow conversion to see how efficiently the company converts income to cash.
Abeona Therapeutics Inc Market Cap History: 2015 to 2026
Abeona Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $4.79 Billion to $309.78 Million (-24.26% CAGR).
Index Memberships
Abeona Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #401 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1444 of 3165 |
Weight: Abeona Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Abeona Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Abeona Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
51.66x
Abeona Therapeutics Inc's market cap is 51.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.22x
Abeona Therapeutics Inc's market cap is 4.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.92 Billion | $889.00K | -$21.87 Million | 7780.87x | N/A |
| 2017 | $22.61 Billion | $837.00K | -$27.32 Million | 27007.98x | N/A |
| 2018 | $10.18 Billion | $3.00 Million | -$56.67 Million | 3396.68x | N/A |
| 2020 | $2.24 Billion | $10.00 Million | -$84.23 Million | 223.92x | N/A |
| 2021 | $480.64 Million | $3.00 Million | -$84.94 Million | 160.21x | N/A |
| 2022 | $175.71 Million | $1.41 Million | -$39.70 Million | 124.27x | N/A |
| 2023 | $285.82 Million | $3.50 Million | -$54.19 Million | 81.66x | N/A |
| 2025 | $300.65 Million | $5.82 Million | $71.18 Million | 51.66x | 4.22x |
Competitor Companies of ABEO by Market Capitalization
Companies near Abeona Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Abeona Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Abeona Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Abeona Therapeutics Inc's market cap moved from $4.79 Billion to $ 309.78 Million, with a yearly change of -24.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $309.78 Million | +3.04% |
| 2025 | $300.65 Million | -5.39% |
| 2024 | $317.76 Million | +11.18% |
| 2023 | $285.82 Million | +62.66% |
| 2022 | $175.71 Million | -63.44% |
| 2021 | $480.64 Million | -78.54% |
| 2020 | $2.24 Billion | -51.99% |
| 2019 | $4.66 Billion | -54.20% |
| 2018 | $10.18 Billion | -54.95% |
| 2017 | $22.61 Billion | +226.80% |
| 2016 | $6.92 Billion | +44.35% |
| 2015 | $4.79 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Abeona Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $292.09 Million USD |
| MoneyControl | $292.09 Million USD |
| MarketWatch | $292.09 Million USD |
| marketcap.company | $292.09 Million USD |
| Reuters | $292.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more